Allogene Therapeutics (ALLO) EBITDA Margin (2021 - 2024)
Allogene Therapeutics' (ALLO) quarterly EBITDA Margin came in at 295327.27% in Q1 2024, up 2459273.0% year-on-year from N/an in Q2 2023, and up 26.45% quarter-over-quarter from 401533.33% in Q4 2023.
Allogene Therapeutics (ALLO) EBITDA Margin (2021 - 2024) Analysis & Trends
Allogene Therapeutics has disclosed EBITDA Margin across 4 years of filings, most recently posting 295327.27% for Q1 2024.
- EBITDA Margin for Q1 2024 came in at 295327.27%, up 2459273.0% year-over-year; the trailing twelve-month figure through Dec 2024 was 1166927.27% (down 83188096.0% YoY), and the FY2024 annual result was 1166927.27%, down 83188096.0% from the prior year.
- EBITDA Margin came in at 295327.27% for Q1 2024 at Allogene Therapeutics, up from 401533.33% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 2.75% in Q4 2021 to a low of 401533.33% in Q4 2023.
- The 4-year median for EBITDA Margin is 276577.27% (2023), against an average of 230243.62%.
- Across the five-year window, EBITDA Margin sank 36247032 bps in 2022 and surged 4093384 bps in 2023, its largest moves.
- Allogene Therapeutics' EBITDA Margin stood at 2.75% in 2021, then tumbled by 13164303 bps to 362473.08% in 2022, then fell by 11 bps to 401533.33% in 2023, then climbed by 26 bps to 295327.27% in 2024.
- The last three EBITDA Margin figures came in at 295327.27% (Q1 2024), 401533.33% (Q4 2023), and 276577.27% (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Allogene Therapeutics | 482.98 Mn | 482.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -295,327.27% |
| Dec 31, 2023 | -401,533.33% |
| Sep 30, 2023 | -276,577.27% |
| Jun 30, 2023 | -350,677.27% |
| Mar 31, 2023 | -319,920.00% |
| Dec 31, 2022 | -362,473.08% |
| Sep 30, 2022 | -317,511.11% |
| Jun 30, 2022 | -128,926.56% |
| Mar 31, 2022 | -218,689.74% |
| Dec 31, 2021 | -2.75% |
| Sep 30, 2021 | -159,693.88% |
| Jun 30, 2021 | -161,747.73% |
| Mar 31, 2021 | -87.06% |